Semaglutide, Tirzepatide Linked to Disproportionate Menstrual Events in Reproductive-Aged Patients
Background
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists are increasingly prescribed for obesity, type 2 diabetes, and polycystic ovary syndrome (PCOS) in reproductive-aged women. While these drugs are highly effective for metabolic management, their potential pleiotropic effects on menstrual physiology, ovulation, and fertility remain under-characterized. Current pharmacovigilance data on specific menstrual outcomes are sparse, creating a knowledge gap regarding comprehensive patient counseling.
Study Design
Researchers conducted a retrospective cohort study using the FDA Adverse Event Reporting System (FAERS) data, analyzing reports through March 2026. The study population was restricted to female patients aged 12-55 years who had received GLP-1RAs. They performed disproportionality and Bayesian analyses to identify significant associations between specific GLP-1RAs and various menstrual events. The analysis focused on semaglutide, tirzepatide, and liraglutide, comparing their reporting profiles against other drugs in the database to detect disproportionate signals.
Results
The analysis revealed distinct signal profiles for different GLP-1RAs regarding menstrual events. Semaglutide demonstrated the broadest signal profile, showing disproportionate reporting across multiple categories. These included heavy menstrual bleeding, intermenstrual bleeding, menstrual clots, oligomenorrhea, and anovulatory cycles. In contrast, tirzepatide generated specific signals for intermenstrual bleeding and menstrual clots, indicating a more focused impact on bleeding patterns. Notably, liraglutide produced no significant signals for any menstrual events in this analysis. These findings suggest that GLP-1RAs may exert pleiotropic effects on menstrual physiology, with varying degrees of impact depending on the specific agent. The presence of signals for anovulatory cycles with semaglutide is particularly noteworthy.
Semaglutide showed disproportionate reporting of heavy menstrual bleeding, intermenstrual bleeding, menstrual clots, oligomenorrhea, and anovulatory cycles.
Key Findings
- Semaglutide showed disproportionate reporting of heavy menstrual bleeding.
- Semaglutide was also linked to intermenstrual bleeding, menstrual clots, oligomenorrhea, and anovulatory cycles.
- Tirzepatide generated signals for intermenstrual bleeding and menstrual clots.
- Liraglutide produced no significant signals for menstrual events.
- GLP-1RAs may have pleiotropic effects on menstrual physiology.
Why It Matters
This study highlights that menstrual health should be an explicit part of counseling for reproductive-aged patients initiating GLP-1RA therapy, especially with semaglutide or tirzepatide. For peptide users and clinicians, understanding these potential side effects allows for proactive monitoring and management of menstrual irregularities, which can impact quality of life and fertility planning. While these are association signals from pharmacovigilance data, they suggest a need for further prospective clinical studies to elucidate mechanisms and establish causality. This information could influence future prescribing practices and patient education, ensuring a more holistic approach to care for individuals using these increasingly popular metabolic agents.
semaglutide
tirzepatide
liraglutide
menstrual-health
reproductive-health
adverse-events